Valent BioSciences LLC announced sales of biostimulant products directly to the U.S. customer base, an initiative that began on October 1. The new operating unit – established in February 2022 – is now fully operational, allowing the company to serve its U.S. market, according to a release.
This transition marks a massive change for Valent BioSciences’ go-to-market strategy.
“As both market volatility and the global population increase, biostimulants can be used to sustainably improve crop performance and ROI,” said Salman Mir, executive vice president and chief operating officer for Valent BioSciences. “Biostimulant products, including our AMF technologies, also support the mission of our parent company, Sumitomo Chemical Co., Ltd., for achieving carbon neutrality by 2050, as well as its global goal of attaining carbon neutrality for society as a whole.”
The newly developed biostimulant business team and salesforce will focus on “discovering, developing and commercializing arbuscular mycorrhizal fungi (AMF) products, among other biostimulants, to sustainably maximize retailer and grower profitability,” shared the release.
Valent BioSciences’ core biostimulant products are marketed under brand names Symvado and Proliant. The company will employ various new tools and digital assets to enhance commercialization of the brands for the U.S. market.
“We recognize that biostimulants can be challenging products for customers to successfully utilize, so we are adapting our strategy to best address customer needs and drive value for all parties,” said Dave Schumacher, vice president of commercial operations at Valent BioSciences.
The company’s new biostimulants business includes numerous technical experts that are accessible to retailers and growers when navigating the complex market segment.
“We have more than 60 years of broad biorational crop enhancement expertise, and this launch incorporates the next generation of tools to help our customers succeed,” said Mir. “We are in an excellent position to lead the biostimulants industry as it transitions to science-driven biostimulant products that positively impact the bottom line.”
Read More:
Valent BioSciences Promotes Salman Mir to Executive Vice President and COO
Valent BioSciences Announces Major Expansion at Its Osage Facility
